{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:28:06Z","timestamp":1768285686080,"version":"3.49.0"},"reference-count":42,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since initial publication of the PARADIGM\u2010HF trial in 2014, sacubitril\/valsartan has been investigated in various settings to establish optimal use, further expanding its indications in patients with heart failure (HF). Although numerous studies have been published, until recently these have primarily involved post hoc analyses from the PARADIGM\u2010HF study itself with a consistent focus on use of sacubitril\/valsartan in patients with HF with reduced ejection fraction (HFrEF). This has led to a gap in the literature regarding utility of sacubitril\/valsartan in other HF subpopulations. The aim of this review is to provide a summary of recent clinical trials further expanding use and guideline recommendations for sacubitril\/valsartan. The findings of 15 studies, including clinical trials and post hoc analyses, are summarized and describe the use of sacubitril\/valsartan in additional HF subpopulations, such as HFrEF following hospitalization for acute decompensated HF and advanced HF, HF with preserved ejection fraction (HFpEF), and HF postmyocardial infarction. In addition, three studies investigating timing of initiation, dose titration regimens, and cost\u2010effectiveness are examined. Select ongoing trials are also reviewed to demonstrate the continued commitment to further advance care of patients with HF. This comprehensive review serves as a resource for health care providers who pursue optimal utilization of sacubitril\/valsartan in their respective clinical practices.<\/jats:p>","DOI":"10.1002\/phar.2730","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T07:09:38Z","timestamp":1664003378000},"page":"837-848","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the evidence for sacubitril\/valsartan across the continuum of heart failure"],"prefix":"10.1002","volume":"42","author":[{"given":"Preston T.","family":"Skersick","sequence":"first","affiliation":[{"name":"UNC Eshelman School of Pharmacy University of North Carolina  Chapel Hill North Carolina USA"},{"name":"GlaxoSmithKline Research Triangle Park  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrian","family":"Proco","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preetika","family":"Sharma\u2010Huynh","sequence":"additional","affiliation":[{"name":"PPD  Morrisville North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9839-2510","authenticated-orcid":false,"given":"Courtney A.","family":"Montepara","sequence":"additional","affiliation":[{"name":"Duquesne University School of Pharmacy Duquesne University  Pittsburgh Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6016-0469","authenticated-orcid":false,"given":"Jo E.","family":"Rodgers","sequence":"additional","affiliation":[{"name":"UNC Eshelman School of Pharmacy University of North Carolina  Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5070062"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000757"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659"},{"key":"e_1_2_10_6_1","unstructured":"FDA Approves New Heart Failure Drug.Latest in cardiology\u2013 American College of Cardiology.https:\/\/www.acc.org\/latest\u2010in\u2010cardiology\/articles\/2015\/07\/08\/10\/00\/fda\u2010approves\u2010new\u2010heart\u2010failure\u2010drug. Accessed August 30 2021."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655"},{"key":"e_1_2_10_11_1","unstructured":"Novartis' Entresto Granted Expanded Indication in Chronic Heart Failure by FDA.Media Releases. Novartis.https:\/\/www.novartis.com\/news\/media\u2010releases\/novartis\u2010entresto\u2010granted\u2010expanded\u2010indication\u2010chronic\u2010heart\u2010failure\u2010fda. Accessed August 30 2021."},{"issue":"1","key":"e_1_2_10_12_1","first-page":"62","article-title":"Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment","volume":"106","author":"Azevedo PS","year":"2016","journal-title":"Arq Bras Cardiol"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2015:9:3"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.649866"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12821"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12843"},{"key":"e_1_2_10_17_1","unstructured":"US Food and Drug Administration.FDA approves new drug to treat heart failure. Press Release July 7 2015.www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm453845.html. Accessed August 30 2021."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000435"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"e_1_2_10_21_1","unstructured":"National Library of Medicine (U.S.).Entresto (LCZ696) in advanced heart failure (LIFE study) (HFN\u2010LIFE);2017. Identifier NCT02816736.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02816736. Accessed Aug 12 2021."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.05.005"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.4567"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2015.14"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000518"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1498"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61227-6"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.18463"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15874"},{"key":"e_1_2_10_32_1","volume-title":"Entresto (sacubitril and valsartan) [package insert]","author":"Novartis Pharmaceutical Companies","year":"2021"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.04.008"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.3651"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054892"},{"key":"e_1_2_10_36_1","unstructured":"PfefferMA.Angiotensin receptor Neprilysin inhibition (ARNI) following acute myocardial infarction: primary results of the PARADISE\u2010MI trial. Presented at the American College of Cardiology Virtual Annual Scientific Session on May 15 2021."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa210508"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.548"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.2822"},{"key":"e_1_2_10_40_1","volume-title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52\u2010Week Study LCZ696 Compared with Enalapril in Pediatric Patients with Heart Failure. ClinicalTrials.Gov"},{"key":"e_1_2_10_41_1","volume-title":"Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients with Chronic Heart Failure and Preserved Ejection Fraction (PERSPECTIVE). ClinicalTrials.Gov"},{"key":"e_1_2_10_42_1","volume-title":"Changes in NT\u2010proBNP and Outcomes, Safety, and Tolerability in HFpEF Patients with Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization and Initiated In\u2010Hospital or Within 30\u2009Days Post\u2010Discharge (PARAGLIDE\u2010HF). ClinicalTrials.Gov"},{"key":"e_1_2_10_43_1","volume-title":"Efficacy and Safety of Sacubitril\/Valsartan Compared with Enalapril on Morbidity, Mortality, and NT\u2010proBNP Change in Patients With CCC (PARACHUTE\u2010HF). ClinicalTrials.Gov"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2730","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2730","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:16:56Z","timestamp":1761059816000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/phar.2730"],"URL":"https:\/\/doi.org\/10.1002\/phar.2730","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"2022-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}